24 Jan 2020

The annual J.P. Morgan Healthcare Conference “is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community” (JPMorgan.com).

This year’s conference covered a wide range of trends in healthcare, from anticipated topics like drug pricing reform, to repeat themes with an unexpected twist (where’s all of the M&A activity?), and everything in between.

In case you missed it, we put together a summary of the top news headlines and best social media commentary capturing the biggest takeaways from JPM 2020.

Top Headlines

Drug Pricing

Big Pharma CEOs Weigh In On Drug Prices At JPM 2020: CNBC

Analysis: Pharma Executives Address Drug Prices At JPM 2020 As Political Pressure For Reform Builds: Barron’s

Drugmakers Exploring New Methods Of Payment For Expensive Medicines: Wall Street Journal

M&A Activity

Pharma Dealmaking Slows At This Year’s JP Morgan Healthcare Conference, Executives Say: FiercePharma 

Lack Of Large Deals Seen As Top Theme At JP Morgan Healthcare Conference So Far: STAT 

The Next Therapeutic Area of Major Innovation?

Neuroscience Field Poised For Drug Development Innovation, Karuna CEO Says: FierceBiotech

Roche Sees Growing Role For Neuroscience This Decade: BioPharma Dive

Digital Health

JPM 2020 Attendees Wary Of Vague “Digital Health” Definition, Address Drug Pricing: CNBC 

Drug Launch Strategies

Novartis Executives Discuss Drug Launch Strategies: FiercePharma 

Merck CEO Ken Frazier Highlights Keytruda Success, Drug Price Challenges, And More: Fox Business 

Year of the Consumer

JPM’s Lisa Gill Says Conference Is Focused On The “Year Of The Consumer:” CNBC’s Mad Money

Social Media Commentary

1. @Chrissyfarr on her top 5 takeaways from #JPM20.

2. @jacqueline_says on the current status of digital health.


3. @AndyBiotech on the “lack of M&A at #JPM20.”

4. @MariaBartiromo on pharma research investments.

5. @Chrissyfarr on unanimous opinions about “health data interoperability.”


For more industry insights, sign up for Healthcare Marketing Daily, follow us on LinkedIn, and don’t forget to return to this space!